Correction

This article refers to:

Characteristics and predictors of infusion-related reactions to rituximab in patients with B-cell non-Hodgkin lymphoma

Article title: Characteristics and predictors of Infusion-Related Reactions to Rituximab in Patients with B-cell Non-Hodgkin Lymphoma

Authors: Nour Faqeer, Rawaa Alrabie, Rand Al-Haddadin and Mohammad Ma’koseh

Journal: Journal of Chemotherapy

DOI: https://doi.org/10.1080/1120009X.2023.2270833

When this article was originally published online Table 1 showed a ‘=’ in place of ‘≥’. The appropriate Table 1 is provided below.

Table 1. The baseline characteristics of patients with infusion related reactions (IRRs) and those without IRRs.

Variable		Total (n = 334) N (%)	IRRs group (n = 100) N (%)	Non-IRRs group (n = 234) N (%)	p-Value
BMI	Underweight (18.5>)	5 (1.5%)	–	5 (2.1%)
	Normal (18–24)	78 (23.3%)	25 (25.0%)	53 (22.6%)
	Overweight (25–29)	120 (36.0%)	29 (29.0%)	91 (38.9%)
	Obese (≥ 30)	131 (39.2%)	46 (46.0%)	85 (36.3%)
BMI ≥ 30	No	203 (60.8%)	54 (54.0%)	149 (63.7%)	0.545
	Yes	131 (39.2%)	46 (46.0%)	85 (36.3%)
Age, years	Mean (SD)		54.7 (13.2)	56.0 (14.8)	0.3004
Gender	Male	196 (58.7%)	58 (58.0%)	138 (59.0%)	0.868
Patients without chronic medical conditions	Yes	141 (42.2%)	44 (44.0%)	97 (41.5%)	0.666
	No	193 (57.8%)	56 (56.0%)	137 (58.5%)
Current smoker	Yes	112 (33.5%)	33 (33.0%)	79 (33.8%)	0.786
	No	222 (66.5%)	67 (67.0%)	155 (66.2%)
History of allergy	Yes	38 (11.4%)	13 (13.0%)	25 (10.7%)	0.541
	No	296 (88.6%)	87 (87.0%)	209 (89.3%)
Lymphoma subtype	DLBCL	218 (65.2%)	58 (58.0%)	160 (68.4%)
	FL	37 (11.1%)	14 (14.0%)	23 (9.8%)
	MZL	36 (10.8%)	19 (19.0%)	17 (7.3%)
	MCL	13 (3.9%)	5 (5.0%)	8 (3.4%)
	BL	8 (2.4%)	1(1.0%)	7 (3.0%)
	High grade B-cell lymphoma	12 (3.6%)	3 (3.0%)	9 (3.8%)
	Others	10 (3.0%)	–	10 (4.3%)
DLBCL versus other subtypes	DLBCL	218 (65.2%)	58 (58.0%)	160 (68.4%)	0.64
	Others	116 (34.8%)	42 (42.0%)	74 (31.6%)
Stage	I	37 (11.0%)	14 (14.0%)	23 (9.4%)
	II	69 (20.7%)	15 (15.2%)	54 (23.2%)
	III	51 (15.3%)	17 (17.2%)	34 (14.6%)
	IV	177 (53.0%)	54 (54.5%)	123 (52.8%)
Early versus advanced stage	Early stage	106 (31.7%)	29 (29.0%)	77 (33.0%)	0.45
	Advanced stage	228 (68.3%)	71 (71.0%)	157 (67.0%)
Histological subtypes	Aggressive lymphoma	258 (77.2%)	67 (67.0%)	191 (81.6%)	0.004
	Indolent lymphoma	76 (22.8%)	33 (33.0%)	43 (18.4%)
Rituximab-containing regimens	RCHOP	209 (62.6%)	63 (63.0%)	146 (62.4%)
	Bendamustine-Rituximab	53 (15.9%)	15 (15.0%)	38 (16.2%)
	DA-REPOCH	39 (11.7%)	4 (4.0%)	35 (15.0%)
	Rituximab alone	13 (3.9%)	12 (12.0%)	1 (0.4%)
	Others	20 (5.9%)	6 (6.0%)	14 (6.0%)
Bulky disease	Yes	114 (34.0%)	33 (33.0%)	81 (34.6%)	0.776
	No	220 (66.0%)	67 (67.0%)	153 (65.4%)
Bone marrow involvement	Yes	71 (21.3%)	30 (30.0%)	41 (17.5%)	0.011
	No	263 (78.7%)	70 (70.0%)	193 (82.5%)
Circulating lymphocytes	Not available	238	–	–	0.188
	No	83 (86.0%)	30 (81.1%)	56 (90.3%)
	Yes	13 (14.0%)	7 (18.9%)	6 (9.7%)
Splenomegaly	Yes	79 (23.6%)	36 (36.0%)	43 (18.4%)	0.001
	No	255 (67.4%)	64 (64.0%)	191 (81.6%)
Premedication with corticosteroids	Yes	234 (70.0%)	64 (64.0%)	170 (72.6%)	0.114
	No	100 (30.0%)	36 (36.0%)	64 (27.4%)
Premedication with hydrocortisone	Yes	43 (12.9%)	5 (5.0%)	38 (16.2%)	0.005
	No	291 (87.1%)	95 (95.0%)	196 (83.7%)
Premedication with dexamethasone	Yes	194 (58.0%)	59 (59.0%)	135 (57.7%)	0.824
	No	140 (42.0%)	41 (41.0%)	99 (42.3%)
LDH	Within normal limit	184 (55.0%)	51 (51.0%)	133 (56.8%)	0.326
	Above upper normal limit	150 (45.0%)	49 (49.0%)	101 (43.2%)
Albumin	≥3.5	253 (75.7%)	82 (82.0%)	171 (73.1%)	0.081
	Less than 3.5	81 (24.3%)	18 (18.0%)	63 (26.9%)
Hemoglobin	Less than 12	156 (46.7%)	49 (49.0%)	107 (45.7%)	0.583
	≥12	178 (53.3%)	51 (51.0%)	127 (54.3%)
ALC	≥2000	244 (73.0%)	65 (65.0%)	179 (76%)	0.032
	<2000	90 (27.0%)	35 (35.0%)	55 (24%)
ANC	>1000	325 (97.3%)	94 (94.0%)	231 (98.7%)	0.023
	≤1000	9 (2.7%)	6 (6.0%)	3 (1.4 %)
Platelet count	>140*10^3	292 (87.4%)	79 (79.0 %)	213 (91.0%)	0.004
	≤140*10^3	42 (12.6%)	21 (21.0%)	21 (9.0%)
Uric acid	Median [IQR]		5.2 (1.1, 9.6)	4.6 (0.4, 20.9)	0.012

BMI: body mass index; SD: standard deviation; IQR: interquartile range; DLBCL: diffuse large B-cell lymphoma; FL: follicular lymphoma; MZL: marginal zone lymphoma; MCL: mantle cell lymphoma; BL: Burkitt’s lymphoma; LDH: lactate dehydrogenase, ALC: absolute lymphocyte count; ANC: absolute neutrophil count; RCHOP: rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone; DA-REPOCH: dose adjusted rituximab, cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisolone.